Internal Medicine, Hematology & Oncology · San Antonio, TX
NPI
1700827839
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
8019 S New Braunfels, Suite 101
San Antonio, TX, 78235
Phone (210) 922-5556
Groups this clinician bills Medicare through
Medicare paid, 2024
$380K
38,745 services
Medicare patients, 2024
147
Average age 75
Drug cost, 2024
$3.7M
1,452 prescriptions
Company payments, 2025
$7,787
From 54 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Syed N Raza was code J1100 (injection, dexamethasone sodium phosphate, 1 mg), 1,988 times for 24 patients. In total Syed N Raza billed 38,745 services in 72 codes, and Medicare paid $380K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-05-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,988 | 24 | $0.08 | $168 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,120 | 11 | $0.07 | $77.92 |
| 99213 Office E&M - Established | Office | 246 | 116 | $66.04 | $16K |
| 96367 Intravenous Infusion, Hydration | Office | 155 | 24 | $20.20 | $3,131 |
| 96372 Injection Administration | Office | 126 | 25 | $10.26 | $1,293 |
| 36415 Venipuncture Blood Collection | Office | 116 | 34 | $8.65 | $1,003 |
| 96413 Chemotherapy Administration | Office | 99 | 16 | $92.67 | $9,175 |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 69 | 17 | $0.60 | $41.35 |
| 96365 Intravenous Infusion, Hydration | Office | 58 | 18 | $43.10 | $2,500 |
| 99214 Office E&M - Established | Office | 56 | 26 | $95.61 | $5,354 |
| 96375 Injection Administration | Office | 44 | 12 | $10.86 | $478 |
| 99214 Office E&M - Established | Facility | 18 | 15 | $65.77 | $1,184 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 16 | 14 | $10.98 | $176 |
By year: 2022 $123K for 9,327 services; 2023 $567K for 39,685 services; 2024 $380K for 38,745 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 116 | 34 | $8.65 | $1,003 |
Medicare prescription drug claims, 2024
In 2024, the drug Syed N Raza prescribed most often to Medicare patients was Dexamethasone, with 108 prescriptions and refills. In total Syed N Raza wrote 1,452 Medicare prescriptions that cost $3.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 108 | 112 | 54 | $2,012 |
| Ondansetron Odt Ondansetron | 106 | 109 | 57 | $1,713 |
| Zarxio Filgrastim-Sndz | 81 | 81 | 29 | $146K |
| Anastrozole Generic | 51 | 127 | 22 | $492 |
| Letrozole Generic | 50 | 136 | 23 | $1,505 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 49 | 49 | 22 | $2,328 |
| Allopurinol Generic | 43 | 54 | 11 | $161 |
| Eliquis Apixaban | 35 | 40 | 13 | $24K |
| Xarelto Rivaroxaban | 34 | 82 | 14 | $48K |
| Prednisone Generic | 31 | 35 | 17 | $132 |
| Revlimid Lenalidomide | 30 | 30 | Under 11 | $609K |
| Gabapentin Generic | 29 | 33 | 12 | $507 |
| Alendronate Sodium Generic | 28 | 64 | 12 | $188 |
| Levothyroxine Sodium Generic | 27 | 41 | Under 11 | $103 |
| Lenalidomide Generic | 27 | 27 | Under 11 | $337K |
Brand drugs: 361 claims; generic drugs: 1,091 claims; opioid claims: 111.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Syed N Raza $7,787 ($7,787 in general payments such as food, travel and fees) from 54 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,406.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 35 | $1,406 |
| US Oncology Corporate, Inc. | 3 | $491 |
| AstraZeneca Pharmaceuticals LP AZN | 22 | $476 |
| Pfizer Inc. PFE | 19 | $355 |
| Janssen Biotech, Inc. JNJ | 17 | $347 |
| Merck Sharp & Dohme LLC MRK | 12 | $292 |
| Aveo Pharmaceuticals, Inc. | 15 | $290 |
| E.R. Squibb & Sons, L.L.C. BMY | 12 | $284 |
| Celgene Corporation BMY | 11 | $282 |
| Daiichi Sankyo Inc. 4568.T | 12 | $225 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.